Brain Cancer
Specialty Channel

Featured Article
True or False: Although the combination of neurosurgical resection and postoperative HSRT is an emerging therapeutic approach for brain metastases, mature large-scale outcome data is currently…
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.
Pembrolizumab is safe and active in certain patients with brain metastases from NSCLC, findings from an open-label clinical trial suggest.
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.
Over time, young patients with severe sensorineural hearing loss face difficulty with reading, and struggle most with phonological skills and processing speed, a recent study shows.
Long-term results from a clinical trial of patients with locally advanced NSCLC has yielded many important findings regarding the use of prophylactic cranial irradiation.
Supplementary study data support the use of neratinib plus capecitabine in the treatment of patients with refractory, HER2-positive breast cancer brain metastases.
Adults who had brain cancer as children may have a harder time living independently and having rich professional and personal lives than people who didn't have these tumors in childhood.

News

In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.
Pembrolizumab is safe and active in certain patients with brain metastases from NSCLC, findings from an open-label clinical trial suggest.
Patients with SCLC who received radiotherapy twice daily were more likely to have brain metastases after prophylactic cranial irradiation than those who received radiotherapy once daily.

Interactive Features

True or False: Although the combination of neurosurgical resection and postoperative HSRT is an emerging therapeutic approach for brain metastases, mature large-scale outcome data is currently…
Stay in the know.
OncNet Newsletter